Atlas Trials

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Clinical trial NCT05287386 · UNKNOWN

Trial details

NCT number
NCT05287386
Sponsor
The First Affiliated Hospital of Xiamen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Non-Small Cell Lung Cancer
Start date
2022-01-21
Primary completion
2024-01-21
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.